CurrentBlue Cross Blue Shield - Rhode IslandPolicy N/A

Skin Contact Monochromatic Infrared Energy as a Technique to Treat Cutaneous Ulcers, Diabetic Neuropathy, and Miscellaneous Musculoskeletal Conditions

Defines coverage for skin contact monochromatic infrared energy (MIRE) devices for treatment of cutaneous ulcers, diabetic neuropathy, musculoskeletal and soft tissue conditions for Commercial Products of Blue Cross Blue Shield - Rhode Island.

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicySkin Contact Monochromatic Infrared Energy as a Technique to Treat Cutaneous Ulcers, Diabetic Neuropathy, and Miscellaneous Musculoskeletal Conditions

Policy CodePolicy N/A

Change TypeNo material change

Effective DateN/A

Next Review DateN/A

Key ActionVerify member-specific benefits with the provider call center before providing services.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

Not medically necessaryCoverage stance

E0221, A4639HCPCS

CommercialApplicability

880 nmWavelength

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Not medically necessary

Covered when ALL of the following are met

Primary coverage determination: Skin contact monochromatic infrared energy is considered not medically necessary as a technique to treat cutaneous ulcers, diabetic neuropathy, and musculoskeletal conditions and any other conditions including, but not limited to, temporomandibular disorders, tendonitis, capsulitis, and myofascial pain.

Applies to Commercial Products; evidence insufficient to determine effect on health outcomes.

This policy applies to Commercial Products of Blue Cross Blue Shield - Rhode Island. For members covered under Medicare, refer to the separate BlueCHiP for Medicare policy and related National and Local Coverage Determinations.

Skin contact monochromatic infrared energy (MIRE) is considered not medically necessary as a technique to treat cutaneous ulcers, diabetic neuropathy, musculoskeletal conditions, and any other conditions including, but not limited to, temporomandibular disorders, tendonitis, capsulitis, and myofascial pain, because the evidence is insufficient to determine the effects of the technology on health outcomes.

Provider Requirements and Actions

Prior Authorization

Prior authorization is not required for skin contact monochromatic infrared energy therapies under this policy.

Documentation Required

Provider Actions

Providers should verify member benefits and eligibility prior to rendering services. For services determined to be not medically necessary or non-covered by the member's contract, do not balance-bill the member unless the member has been informed and provided written agreement to proceed at their own expense. For member-specific coverage questions, contact the provider call center.

Note

Benefit Verification

Benefits and coverage vary by contract. Refer to the member's Benefit Booklet or Subscriber Agreement for applicable coverage determinations and whether services are considered not medically necessary or not covered.

Denial Risk

Denial Risk / Not Medically Necessary Codes

There is a denial risk for the use of MIRE services/devices and the following HCPCS codes when billed for treatment of cutaneous ulcers, diabetic neuropathy, musculoskeletal conditions, or other indications cited in this policy because they are considered not medically necessary.

E0221 - Infrared heating pad system
A4639 - Replacement pad for infrared heating pad system, each

Background

Monochromatic Infrared Energy (MIRE) refers to devices that deliver near-infrared light through skin-contact pads and have been investigated for a range of indications including cutaneous ulcers, diabetic neuropathy, and musculoskeletal and soft tissue injuries. Proposed mechanisms in the literature include photobiostimulation and increased local circulation, but available evidence is inadequate to establish clinical benefit for the listed indications.

Definitions

MIRE (Monochromatic Infrared Energy) — device and wavelength

WavelengthApproximately 880 nm (near-infrared).

Delivery methodSkin-contact pads containing arrays of superluminous infrared diodes (about 60 diodes per pad).

Session durationTypical treatment sessions last about 30–45 minutes.

Proposed actionsPurported mechanisms include photobiostimulation and increased local circulation possibly via increased plasma nitric oxide.

Regulatory example devicesAnodyne Professional Therapy System (FDA 510[k] cleared, 1994); Clarimedix SMI™ SpectroPad (510[k] K062635); Bioremedi HealthLight System (510[k] K101894).